|
|
.
See Category: Factors influencing health status and contact with health services
See Header: Encntr screen for malignant neoplasm of intestinal tract
ICD-10 (CM) Code and Descriptor
|
Z12.12 |
Encounter for screening for malignant neoplasm of rectum
This code is considered unacceptable as a principal diagnosis.
|
Z1212 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 3.70%
|
20.64%
|
8.73%
|
8.70%
|
9.31%
|
9.26%
|
8.28%
|
7.43%
|
6.02%
|
4.79%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for Z12.12*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
82274
|
ASSAY TEST FOR BLOOD FECAL |
1,389
|
1,389
|
|
G0328
|
FECAL BLOOD SCRN IMMUNOASSAY |
701
|
701
|
|
82270
|
OCCULT BLOOD FECES |
499
|
504
|
|
80053
|
COMPREHEN METABOLIC PANEL |
338
|
338
|
|
80061
|
LIPID PANEL |
331
|
331
|
|
85025
|
COMPLETE CBC W/AUTO DIFF WBC |
305
|
305
|
|
36415
|
COLL VENOUS BLD VENIPUNCTURE |
291
|
291
|
|
J2704
|
INJ, PROPOFOL, 10 MG |
282
|
7,274
|
|
84443
|
ASSAY THYROID STIM HORMONE |
252
|
252
|
|
88305
|
TISSUE EXAM BY PATHOLOGIST |
168
|
270
|
|
83036
|
HEMOGLOBIN GLYCOSYLATED A1C |
155
|
155
|
|
82306
|
VITAMIN D 25 HYDROXY |
149
|
149
|
|
81001
|
URINALYSIS AUTO W/SCOPE |
128
|
128
|
|
88112
|
CYTOPATH CELL ENHANCE TECH |
103
|
103
|
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
99
|
100
|
|
G0101
|
CA SCREEN;PELVIC/BREAST EXAM |
88
|
88
|
|
J2001
|
LIDOCAINE INJECTION |
86
|
573
|
|
82607
|
VITAMIN B-12 |
77
|
77
|
|
Q0091
|
OBTAINING SCREEN PAP SMEAR |
72
|
72
|
|
82043
|
UR ALBUMIN QUANTITATIVE |
64
|
64
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
Z12.12 related to the following DRG Codes:
951
|
